Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 2

Year

2020 2

Keywords

Coronavirus disease 2019 2

Efficacy 2

Safety 2

Triazavirin 2

Pneumonia 1

SARS-CoV-2 1

open ︾

Search scope:

排序： Display mode:

The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol Protocol

Xiaoke Wu, Kaijiang Yu, Yongchen Wang, Wanhai Xu, Hongli Ma, Yan Hou, Yue Li, Benzhi Cai, Liying Zhu, Min Zhang, Xiaoli Hu, Jingshu Gao, Yu Wang, Huichao Qin, Mingyan Zhao, Yong Zhang, Kang Li, Zhimin Du, Baofeng Yang

Engineering 2020, Volume 6, Issue 10, Pages 1199-1204 doi: 10.1016/j.eng.2020.06.011

Abstract: conducted at ten study sites in Heilongjiang Province, China, to investigate the efficacy and safety of Triazavirin

Keywords： Coronavirus disease 2019 Pneumonia SARS-CoV-2 Triazavirin Efficacy Safety

HTML PDF Collect

Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Article

Xiaoke Wu, Kaijiang Yu, Yongchen Wang, Wanhai Xu, Hongli Ma, Yan Hou, Yue Li, Benzhi Cai, Liying Zhu, Min Zhang, Xiaoli Hu, Jingshu Gao, Yu Wang, Huichao Qin, Wenjie Wang, Mingyan Zhao, Xia Wu, Yong Zhang, Lu Li, Kang Li, Zhimin Du, Ben Willem J. Mol, Baofeng Yang

Engineering 2020, Volume 6, Issue 10, Pages 1185-1191 doi: 10.1016/j.eng.2020.08.011

Abstract: To assess the efficacy and safety of Triazavirin therapy for COVID-19, we conducted a randomized, double-blindedPatients were treated with Triazavirin 250 mg versus a placebo three or four times a day for 7 d.We randomized 52 patients for treatment with Triazavirin (n = 26) or a placebo (n = 26)Patients in the Triazavirin group used less frequent concomitant therapies for respiratory, cardiac,Although no statistically significant evidence was found to indicate that Triazavirin benefits COVID-

Keywords： Coronavirus disease 2019 Triazavirin Efficacy Safety